Feb 19, 2019 Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
Jan 28, 2019 Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
Jan 22, 2019 FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
Oct 31, 2018 Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
Oct 30, 2018 Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism
